Loading…
Zymeworks Inc. is projected to rise to $30.80 by 2027, a +36% move from its current price of $22.71. ZYME is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $22.26 | $22.73 | $23.21 | +0.09% |
| Aug 2 | $22.09 | $22.75 | $23.43 | +0.18% |
| Aug 3 | $21.96 | $22.77 | $23.61 | +0.27% |
| Aug 4 | $21.86 | $22.79 | $23.76 | +0.36% |
| Aug 5 | $21.77 | $22.81 | $23.90 | +0.45% |
| Aug 6 | $21.69 | $22.83 | $24.03 | +0.54% |
| Aug 7 | $21.62 | $22.85 | $24.15 | +0.63% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.62 | $22.85 | $24.15 | +0.63% |
| Week 2 | $21.27 | $22.99 | $24.86 | +1.25% |
| Week 3 | $21.03 | $23.14 | $25.46 | +1.89% |
| Week 4 | $20.85 | $23.28 | $26.00 | +2.53% |
| Week 5 | $20.71 | $23.43 | $26.51 | +3.17% |
| Week 6 | $20.59 | $23.58 | $26.99 | +3.81% |
| Week 7 | $20.50 | $23.72 | $27.45 | +4.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zymeworks Inc. is a biotechnology company that develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. Its platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc.
Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
ZYME is a biotechnology stock in the Healthcare sector. The current price is $22.01 and the market cap is $1.62B. The asset is ranked 2199 in market capitalization.
A major floor 16.9% below — a decisive break under it would weaken the trend.
The nearest floor, 3.1% below — buyers have tended to step in here.
The nearest ceiling, 19.2% above — a clean break opens room to run.
A major ceiling 27.7% above — clearing it would confirm fresh momentum.
Key ZYME support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZYME market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.64 | Buy | $22.70 | Buy |
| MA 10 | $23.17 | Sell | $23.16 | Sell |
| MA 20 | $24.40 | Sell | $23.74 | Sell |
| MA 50 | $24.28 | Sell | $24.30 | Sell |
| MA 100 | $24.98 | Sell | $24.33 | Sell |
| MA 200 | $23.96 | Sell | $22.96 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.03 | Neutral |
| Stoch RSI (14) | 42.91 | Neutral |
| CCI (20) | -89.74 | Neutral |
| Williams %R (14) | -76.11 | Info |
| MACD (12,26,9) | -0.25 | Sell |
| ROC (12) | -7.91 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 23.89 | Neutral |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -1.52 | Sell |
| Ultimate (7,14,28) | 28.77 | Buy |
| Momentum (10) | -1.48 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 22.21 | Buy |
| ADX (14) | 17.99 | Neutral |
| ATR (14) | 0.48 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 30, indicating a balanced momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.01 | $22.71 | $33.37 | 0% | Neutral | |
| $25.09 | $30.80 | $39.63 | +36% | Bullish | |
| $28.06 | $35.18 | $46.64 | +55% | Bullish | |
| $31.21 | $39.81 | $54.01 | +75% | Bullish | |
| $32.17 | $41.66 | $57.65 | +83% | Bullish | |
| $35.47 | $46.56 | $65.54 | +105% | Bullish | |
| $39.41 | $52.40 | $74.91 | +131% | Bullish | |
| $46.43 | $62.46 | $90.55 | +175% | Bullish | |
| $53.79 | $73.19 | $107.48 | +222% | Bullish | |
| $55.38 | $76.15 | $113.19 | +235% | Bullish | |
| $81.40 | $117.40 | $183.60 | +417% | Bullish | |
| $148.42 | $231.87 | $390.81 | +921% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $22.01 | $22.71 | $26.48 | +0.00% |
| August 2026 | $20.49 | $23.93 | $28.51 | +5.36% |
| September 2026 | $20.96 | $24.63 | $29.65 | +2.94% |
| October 2026 | $21.15 | $24.98 | $30.32 | +1.41% |
| November 2026 | $21.95 | $26.04 | $31.81 | +4.23% |
| December 2026 | $22.81 | $27.16 | $33.37 | +4.30% |
Click any year to see its month-by-month ZYME forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Zymeworks Inc.'s 2026 outlook centres on $22.71, within a $22.01 to $33.37 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ZYME could reach as high as $39.63, with a base case around $30.80 and support toward $25.09 — roughly +36% from $22.71. Buyers look set to stay in control over this stretch.
Expect ZYME to range from $28.06 to $46.64 through 2028. The $35.18 average target implies a +55% move from current prices. That is up +14% on the projected 2027 average. Momentum favours further upside here.
The ZYME price prediction for 2029 points to an average of $39.81 (low $31.21, high $54.01) — a potential gain of +75% on today's $22.71. Buyers look set to stay in control over this stretch.
In 2030, ZYME is projected to trade between $32.17 and $57.65, averaging $41.66 — a potential gain of +83% from today's $22.71. That is up +5% on the projected 2029 average. Momentum favours further upside here.
Zymeworks Inc.'s 2031 outlook centres on $46.56, within a $35.47 to $65.54 range. That is up +12% on the projected 2030 average. That marks a +105% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ZYME could reach as high as $74.91, with a base case around $52.40 and support toward $39.41 — roughly +131% from $22.71. Momentum favours further upside here.
Expect ZYME to range from $46.43 to $90.55 through 2033. The $62.46 average target implies a +175% move from current prices. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ZYME price prediction for 2034 points to an average of $73.19 (low $53.79, high $107.48) — a potential gain of +222% on today's $22.71. Momentum favours further upside here.
In 2035, ZYME is projected to trade between $55.38 and $113.19, averaging $76.15 — a potential gain of +235% from today's $22.71. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Zymeworks Inc.'s 2040 outlook centres on $117.40, within a $81.40 to $183.60 range. That is up +54% on the projected 2035 average. That marks a +417% change versus current levels. Momentum favours further upside here.
By 2050, ZYME could reach as high as $390.81, with a base case around $231.87 and support toward $148.42 — roughly +921% from $22.71. Buyers look set to stay in control over this stretch.
Investing $1,000 in ZYME today (≈ 44.033465 ZYME) could be worth
$10,209.88
+$9,209.88 (+921%) by 2050 · US Dollar
Based on the average projected ZYME price of $231.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZYMEwould be worth at today's price.
$1,000 invested in ZYME on Jul 30, 2025 (≈ 77.279755 ZYME) would be worth
$1,755.02
+$755.02 (+75.5%) today · 1.76× · US Dollar
Based on a ZYME entry price of $12.94 vs. today's $22.71.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.12 | $982.27 | -1.8% |
| 1 month ago | $26.14 | $868.78 | -13.1% |
| 3 months ago | $26.61 | $853.44 | -14.7% |
| 6 months ago | $22.53 | $1,007.99 | +0.8% |
| 1 year ago | $12.94 | $1,755.02 | +75.5% |
| All time (5.0y) ago | $32.04 | $708.8 | -29.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZYME forecast.
Our base-case forecast reaches $45.00 around 2031.
Implied market cap at $45.00: $3.29B
The multi-year forecast shows bullish sentiment from 2027 onward, with a steady rise in the average price and readers of return on investment. For 2027 the avg price is $29.50 with a 34% ROI; for 2028 the avg is $33.50 with a 52.2% ROI; for 2029 the avg is $37.59 with a 70.8% ROI; for 2030 the avg is $39.01 with a 77.2% ROI. The uptrend continues through 2040 with an avg of $105.09 and a 377.5% ROI, and culminates in 2050 with an avg of $204.83 and an 830.6% ROI.
These figures illustrate a strong long-term upside but are estimates, not guarantees, and they should be interpreted with appropriate caution.
Tap a question to reveal the answer.
2030 average price is $39.01 with a minimum of $30.17 and a maximum of $53.84; ROI is 77.2% and sentiment is BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages and ROI, including 2027 avg $29.50 and 2050 avg $204.83 with ROI reaching 830.6%. Remember these are estimates, not guarantees.
Yes. The forecast lists a maximum of $50.89 in 2029 and $53.84 in 2030.
The 30-day range is between $19.22 and $25.20.
Current price is $22.01 and market cap is $1.62B.
Zymeworks Inc. Community Discussion
0Share your Zymeworks Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.